

MONOCLONAL VHH NANOBODIES





Your In Vivo CRO LEADERS

LAMPIRE'S CUTTING-EDGE LLAMA VHH ANTIBODY APPROACH

Are you ready to revolutionize your monoclonal antibody discovery process? Look no further than LAMPIRE's innovative Llama B Cell approach. Leveraging our extensive expertise in Llama and Alpaca immunizations, we've developed a proprietary process for Single Cell Sorting of Target-Positive Llama and Alpaca B cells, paving the way for rapid and cost-effective monoclonal antibody discovery.

Time Advantage: With our Llama B Cell approach, you'll experience the quickest timeline to a validated vHH binder. vHH sequences are recovered within 3 weeks of PBMC isolation, ensuring swift progress towards your research goals.

Cost Efficiency: Save on expenses without compromising quality, by eliminating the costs associated with phage or yeast library creation and panning. With our process, duplicate clones are eliminated during the initial recovery phase prior to screening, maximizing resource utilization.

Full Diversity from Immunized Animals: Our approach enables you to capture the entire antibody repertoire, empowering you to explore the relationship between sequence clonotype and affinity/epitope.

CMC and **Developability for Therapeutics:** Through in silico assessment of predicted developability risks, human-ness, and immunogenicity potential, you can streamline the selection process. And for those seeking additional refinement, we offer optional services such as sequence liability removal and humanization.

Contact us today (215) 795-2838 / sales@lampire.com to learn more about how you can accelerate your antibody discovery with LAMPIRE's Llama B Cell technology.

SOCIAL MEDIA

Subscribe, Like, Comment

in LINKEDIN

Y TWITTER

(C) INSTAGRAM

f FACEBOOK

YOUTUBE

CONTACT US

(e) LAMPIRE@LAMPIRE.COM

(w) WWW.LAMPIRE.COM

(p) (215) 795-2838

(f) (215) 795-0237

APPEARANCE



Düsseldorf, Germany Location: Hall 1, Booth #B44